CI Investments Inc
DNLI icon

CI Investments Inc’s Denali Therapeutics DNLI Stock Holding History

CI Investments Inc’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4
Closed – – 1280
2022
Q1 		$0 Hold
4
– – ﹤0.01% 1327
2021
Q4 		$0 Hold
4
– – ﹤0.01% 1311
2021
Q3 		$0 Buy
+4
New +$225 ﹤0.01% 1289

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

CI Investments Inc's DNLI Position: Q2 2022 in Review

CI Investments Inc sold out of Denali Therapeutics (DNLI) in Q2 2022, closing a stake of 4 shares.

CI Investments Inc first reported a position in DNLI in Q3 2021 and held it in 3 quarters. The position peaked at $0 in Q1 2022. 188 funds tracked by Wall St. Rank hold DNLI as of Q2 2022.

  • CI Investments Inc reported no remaining Denali Therapeutics position as of Q2 2022 after selling out during the quarter.
  • CI Investments Inc sold 4 Denali Therapeutics shares in Q2 2022.
  • CI Investments Inc first reported a position in Denali Therapeutics in Q3 2021 and held it in 3 quarters.
  • CI Investments Inc's Denali Therapeutics position peaked at $0 in Q1 2022.
  • 188 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2022.

Based on CI Investments Inc's 13F filing for Q2 2022, filed 12 Aug 2022.